Ovid Therapeutics Launches Pipeline Teach-In Webinar Series
June 04 2020 - 7:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical
company committed to developing medicines that transform the lives
of people with rare neurological diseases, today announced that it
will host an educational webinar series featuring external experts
to review the Company’s pipeline programs.
Ovid will host its first webinar on Wednesday, June 17, at 1:00
p.m. ET to review the Company’s OV935 (soticlestat) development
program for rare developmental and epileptic encephalopathies (DEE)
in advance of topline results from the randomized Phase 2 ELEKTRA
trial in Dravet syndrome and Lennox-Gastaut syndrome (LGS),
expected in the third quarter of 2020.
June 17 Webinar Presenters:
- Scott Demarest, M.D. – Assistant Professor of Pediatrics and
Neurology at the University of Colorado
- Jeremy M. Levin, DPhil, MB BChir – Chairman and Chief Executive
Officer at Ovid Therapeutics
- Amit Rakhit, M.D., MBA – President and Chief Medical Officer at
Ovid Therapeutics
- Jason Tardio – Chief Commercial Officer at Ovid
Therapeutics
- Julia Tsai, Ph.D. – VP, Clinical Development - Epilepsy at Ovid
Therapeutics
Ovid anticipates holding a second educational webinar later in
2020 to review the Company’s OV101 (gaboxadol) development program
for Angelman syndrome and Fragile X syndrome.
June 17 Webinar Registration and
InformationPlease register for the webinar through the
Events & Presentations section of the Company's website at
https://investors.ovidrx.com/news-events/presentations-events. An
archived replay of the webcast will be available on the Company's
website for 90 days following the live event.
About Ovid TherapeuticsOvid Therapeutics Inc.
is a New York-based biopharmaceutical company using its
BoldMedicine® approach to develop medicines that transform the
lives of patients with rare neurological disorders. Ovid has a
broad pipeline of potential first-in-class medicines. The Company’s
most advanced investigational medicine, OV101 (gaboxadol), is
currently in clinical development for the treatment of Angelman
syndrome and Fragile X syndrome. Ovid is also developing OV935
(soticlestat) in collaboration with Takeda Pharmaceutical Company
Limited for the potential treatment of rare developmental and
epileptic encephalopathies (DEE). For more information on Ovid,
please visit http://www.ovidrx.com/.
Contacts
Investors and Media:Ovid Therapeutics
Inc.Investor Relations & Public Relationsirpr@ovidrx.com
Or
Investors: Steve KlassBurns McClellan,
Inc.sklass@burnsmc.com (212) 213-0006
Media: Katie Engleman 1AB katie@1abmedia.com
(919) 333-7722
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2024 to May 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From May 2023 to May 2024